Patents by Inventor Jonathan E Grob

Jonathan E Grob has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Complement pathway modulators and uses thereof
    Patent number: 9452990
    Abstract: The present invention provides a compound of formula I a method for manufacturing the compounds of the invention, and its therapeutic uses as inhibitor of the complement alternative pathway and particularly as inhibitor of Factor B for the treatment of e.g. age-related macular degeneration and diabetic retinopathy. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: June 19, 2013
    Date of Patent: September 27, 2016
    Assignee: NOVARTIS AG
    Inventors: Michael Dechantsreiter, Jonathan E. Grob, Aengus Macsweeney, Wolfgang Miltz, Stefan Andreas Randl, Richard Sedrani, Holger Sellner, Finton Sirockin, Eric Valeur
  • Complement Pathway Modulators and Uses Thereof
    Publication number: 20150126492
    Abstract: The present invention provides a compound of formula I a method for manufacturing the compounds of the invention, and its therapeutic uses as inhibitor of the complement alternative pathway and particularly as inhibitor of Factor B for the treatment of e.g. age-related macular degeneration and diabetic retinopathy. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: June 19, 2013
    Publication date: May 7, 2015
    Applicant: NOVARTIS AG
    Inventors: Michael Dechantsreiter, Jonathan E. Grob, Aengus Macsweeney, Wolfgang Miltz, Stefan Andreas Randl, Richard Sedrani, Holger Sellner, Finton Sirockin, Eric Valeur
  • Selective hydroxamate based MMP inhibitors
    Patent number: 8314148
    Abstract: The present invention provides a compound of formula (I): said compound is inhibitor of MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-9, and/or MMP-12 and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition.
    Type: Grant
    Filed: May 11, 2012
    Date of Patent: November 20, 2012
    Assignee: Novartis AG
    Inventors: Thomas Leutert, Jonathan E. Grob, Ruben Alberto Tommasi, Erin Keaney, Ayako Honda
  • SELECTIVE HYDROXAMATE BASED MMP INHIBITORS
    Publication number: 20120225882
    Abstract: The present invention provides a compound of formula (I): said compound is inhibitor of MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-9, and/or MMP-12 and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition.
    Type: Application
    Filed: May 11, 2012
    Publication date: September 6, 2012
    Applicant: NOVARTIS AG
    Inventors: Thomas Leutert, Jonathan E. Grob, Ruben Alberto Tommasi, Erin E. Pusateri, Ayako Honda
  • Selective hydroxamate based MMP inhibitors
    Patent number: 8232427
    Abstract: The present invention provides a compound of formula (I): said compound is inhibitor of MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-9, and/or MMP-12 and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition.
    Type: Grant
    Filed: March 27, 2007
    Date of Patent: July 31, 2012
    Assignee: Novartis AG
    Inventors: Thomas Leutert, Jonathan E Grob, Ruben Alberto Tommasi, Erin E. Pusateri, Ayako Honda
  • SELECTIVE HYDROXAMATE BASED MMP INHIBITORS
    Publication number: 20090318511
    Abstract: The present invention provides a compound of formula (I): said compound is inhibitor of MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-9, and/or MMP-12 and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition.
    Type: Application
    Filed: March 27, 2007
    Publication date: December 24, 2009
    Inventors: Thomas Leutert, Jonathan E. Grob, Ruben Alberto Tommasi, Erin E. Pusateri, Ayako Honda
  • Carboxyamine Compounds and Methods of Use Thereof
    Publication number: 20080255149
    Abstract: The invention relates to the use of carboxyamine compounds and salts thereof in the treatment of HDAC dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases.
    Type: Application
    Filed: September 25, 2006
    Publication date: October 16, 2008
    Inventors: Markus Rolf Dobler, Jonathan E. Grob, Arup Patnaik, Branko Radetich, Micheal Shultz, Yanyi Zhu